On the benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells

详细信息    查看全文

• 作者：Hadi Esmaily (1)
  Azadeh Hosseini-Tabatabaei (1)
  Reza Rahimian (1)
  Reza Khorasani (1)
  Maryam Baeeri (1)
  Ahmadreza Barazesh-Morgani (1)
  Nargues Yasa (2)
  Yassaman Khademi (1)
  Mohammad Abdollahi (1)
  
• 关键词：Silymarin ; Inflammatory bowel disease ; Myeloperoxidase ; Malondialdehyde ; Inflammatory cytokines
• 刊名：Central European Journal of Biology
• 出版年：2009
• 出版时间：June 2009
• 年：2009
• 卷：4
• 期：2
• 页码：204-213
• 全文大小：1946KB
• 参考文献：1. Hosseini-Tabatabaei A., Abdollahi M., Potassium channel openers and improvement of toxic stress: Do they have role in the management of inflammatory bowel disease?, Inflamm. Allergy Drug Targets, 2008, 7, 129-35 CrossRef
  2. Kucharzik T., Maaser C., Lügering A., Kagnoff M., Mayer L., Targan S., et al., Recent understanding of IBD pathogenesis: implications for future therapies, Inflamm. Bowel Dis., 2006, 12, 1068-083 CrossRef
  3. Scaldaferri F., Fiocchi C., Inflammatory bowel disease: progress and current concepts of etiopathogenesis, J. Dig. Dis., 2007, 8, 171-78 CrossRef
  4. Rezaie A., Parker R.D., Abdollahi M., Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?, Dig. Dis. Sci., 2007, 52, 2015-021 CrossRef
  5. Blokhina O., Virolainen E., Fagerstedt K.V., Antioxidants, oxidative damage and oxygen deprivation stress: a review, Ann. Bot. (Lond.), 2003, 91, 179-94 CrossRef
  6. Wink D.A., Miranda K.M., Espey M.G., Cytotoxicity related to oxidative and nitrosative stress by nitric oxide, Exp. Biol. Med., 2001, 226, 621-23
  7. Nayar M., Rhodes J.M., Management of inflammatory bowel disease, Postgrad. Med. J., 2004, 80, 206-13 CrossRef
  8. Langmead L., Rampton D.S., Review article: complementary and alternative therapies for inflammatory bowel disease, Aliment. Pharmacol. Ther., 2006, 23, 341-49
  9. Dubinsky M.C., Targeting therapy in pediatric inflammatory bowel disease, Curr. Treat Options Gastroenterol., 2004, 7, 391-05 CrossRef
  10. Ebrahimi F., Esmaily H., Baeeri M., Mohammadirad A., Fallah S., Abdollahi M., Molecular evidences on the benefits of N-acetylcysteine in experimental colitis, Cent. Eur. J. Biol., 2008, 3, 135-42 CrossRef
  11. Hosseini-Tabatabaei A., Esmaily H., Rahimian R., Khorasani R., Baeeri M., Barazesh-Morgani A., et al., Benefits of nicorandil using an immunologic murine model of experimental colitis, Cent. Eur. J. Biol., [Epub ahead of print], DOI: 10.2478/s11535-008-0047-0
  12. Elahi B., Nikfar S., Derakhshani S., Vafaie M., Abdollahi M., On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: A meta-analysis of controlled clinical trials, Dig. Dis. Sci., 2007, 53, 1278-284 CrossRef
  13. Rezaie A., Taghavi-Bayat B., Abdollahi M., Biologic management of fistulizing Crohn’s disease, Int. J. Pharmacol., 2005, 1, 17-4 CrossRef
  14. Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A metaanalysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission, Arch. Med. Sci., 2008, 4, 185-90
  15. Rahimi R., Nikfar S., Rahimi F., A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease, Dig. Dis. Sci., 2008, 53, 2524-531 CrossRef
  16. Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A metaanalysis of antibiotic therapy for active ulcerative colitis, Dig. Dis. Sci., 2007, 52, 2920-925 CrossRef
  17. Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A meta-analysis of broad spectrum antibiotic therapy in patients with active Crohn’s disease, Clin. Ther., 2006, 28, 1983-988 CrossRef
  18. Nikfar S., Rahimi R., Rezaie A., Abdollahi M., A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis, Dig. Dis. Sci., 2008 [Epub ahead of print], DOI: 10.1007/s10620-008-0481-x
  19. Rahimi R., Nikfar S., Rezaie A., Abdollahi M., Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: A meta-analysis, Dig. Dis. Sci., 2008 [Epub ahead of print], DOI: 10.1007/s10620-008-0428-2
  20. Rahimi R., Nikfar S., Rezaie A., Abdollahi M., Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis, Reprod. Toxicol., 2008, 25, 271-75 CrossRef
  21. Ashtaral-Nakhai L., Mohammadirad A., Yasa N., Minaie B., Nikfar S., Ghazanfari G., et al., Benefits of Zataria multiflora boiss in experimental model of mouse inflammatory bowel disease, Evid. Based Complement. Alternat. Med., 2007, 4, 43-0 CrossRef
  22. Ghafari H., Yasa N., Mohammadirad A., Dehghan G., Zamani M.J., Nikfar S., et al., Protection by Ziziphora clinopoides of acetic acid-induced toxic bowel inflammation through reduction of cellular lipid peroxidation and myeloperoxidase activity, Hum. Exp. Toxicol., 2006, 25, 325-32 CrossRef
  23. Ghazanfari G., Minaie B., Yasa N., Nakhai L., Mohammadirad A., Nikfar S., et al., Biochemical and histopathological evidences for beneficial effects of Satureja khuzestanica jamzad essential oil on the mouse model of inflammatory bowel diseases, Toxicol. Mech. Methods, 2006, 16, 365-72 CrossRef
  24. Rahimi R., Mozaffari S., Abdollahi M., On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies, Dig. Dis. Sci., 2008 [Epub ahead of print], DOI: 10.1007/s10620-008-0368-x
  25. Pradhan S.C., Girish C., Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine, Indian. J. Med. Res., 2006, 124, 491-04
  26. Toklu H.Z., Tunali Akbay T., Velioglu-Ogunc A., Ercan F., Gedik N., Keyer-Uysal M., et al., Silymarin, the antioxidant component of Silybum marianum, prevents sepsis-induced acute lung and brain injury, J. Surg. Res., 2008, 145, 214-22 CrossRef
  27. Rainone F., Milk thistle, Am. Fam. Physician., 2005, 72, 1285-288
  28. Gazák R., Walterová D., Kren V., Silybin and silymarin—new and emerging applications in medicine, Curr. Med. Chem., 2007, 14, 315-38 CrossRef
  29. Luper S., A review of plants used in the treatment of liver disease: part 1, Altern. Med. Rev., 1998, 3, 410-21
  30. Kang J.S., Jeon Y.J., Park S.K., Yang K.H., Kim H.M., Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1beta and prostaglandin E2 synthesis by silymarin, Biochem. Pharmacol., 2004, 67, 175-81 CrossRef
  31. Sanchez-Mu?oz F., Dominguez-Lopez A., Yamamoto-Furusho J.K., Role of cytokines in inflammatory bowel disease, World J. Gastroenterol., 2008, 14, 4280-288 CrossRef
  32. Kang J.S., Jeon Y.J., Kim H.M., Han S.H., Yang K.H., Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharidestimulated macrophages. J. Pharmacol. Exp. Ther., 2002, 302, 138-44 CrossRef
  33. Barrachina M.D., Panés J., Esplugues J.V., Role of nitric oxide in gastrointestinal inflammatory and ulcerative diseases: perspective for drugs development, Curr. Pharm. Des., 2001, 7, 31-8 CrossRef
  34. Jahanshahi G., Motavasel V., Rezaie A., Hashtroudi A.A., Daryani N.E., Abdollahi M., Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases, Dig. Dis. Sci., 2004, 49, 1752-757 CrossRef
  35. Manna S.K., Mukhopadhyay A., Van N.T., Aggarwal B.B., Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis, J. Immunol., 1999, 163, 6800-809
  36. Angulo P., Jorgensen R.A., Kowdley K.V., Lindor K.D., Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study, Dig. Dis. Sci., 2008, 53, 1716-720 CrossRef
  37. Saller R., Meier R., Brignoli R., The use of silymarin in the treatment of liver diseases., Drugs, 2001, 61, 2035-063 CrossRef
  38. Abdollahi M., Dehpour A.R., Baharnouri G., Alteration by rubidium of rat submandibular secretion of protein and N-acetyl -D-glucosaminidase, Toxic. Subst. Mech., 1998, 17, 121-31 CrossRef
  39. Wallace J.L., Keenan C.M., Gale D., Shoupe T.S., Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis, Gastroenterology, 1992, 102, 18-7
  40. Dehghan G., Shafiee A., Ghahremani M.H., Ardestani S.K., Abdollahi M., Antioxidant potential of various extracts from ferula szovitsiana in relation to their phenolic content, Pharm. Biol.. 2007,45, 691-99
  41. Astaneie F., Afshari M., Mojtahedi A., Mostafalou S., Zamani M.J., Larijani B., et al., Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients, Arch. Med. Res., 2005, 36, 376-81 CrossRef
  42. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J., Protein measurement with the Folin phenol reagent, J. Biol. Chem., 1951, 193, 265-75
  43. Torres M.I., García-Martin M., Fernández M.I., Nieto N., Gil A., Ríos A., Experimental colitis induced by trinitrobenzenesulfonic acid: an ultrastructural and histochemical study, Dig. Dis. Sci., 1999, 44, 2523-529 CrossRef
  44. Kolgazi M., Jahovic N., Yüksel M., Ercan F., Alican I., α-lipoic acid modulates gut inflammation induced by trinitrobenzene sulfonic acid in rats, J. Gastroenterol. Hepatol., 2007, 22, 1859-865 CrossRef
  45. Jurjus A.R., Khoury N.N., Reimund J.M., Animal models of inflammatory bowel disease, J. Pharmacol. Toxicol. Method., 2004, 50, 81-2 CrossRef
  46. Shen C., De Hertogh G., Bullens D.M., Van Assche G., Geboes K., Rutgeerts P., et al., Remissioninducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization?. Inflamm. Bowel Dis., 2007, 13, 308-16 CrossRef
  47. Rahimi R., Nikfar S., Abdollahi M., Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn’s disease? A systematic meta-analysis of controlled clinical trials, Biomed. Pharmacother., 2007, 61, 75-0 CrossRef
  48. Rahimi R., Nikfar S., Abdollahi M., Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids, Med. Sci. Monit., 2007, 13, PI13–PI18
  49. Simmonds N.J., Rampton D.S., Inflammatory bowel disease - a radical view, Gut, 1993, 34, 865-68 CrossRef
  50. Rogler G., Andus T., Cytokines in inflammatory bowel disease, World J. Surg., 1998, 22, 382-89 CrossRef
  51. Grulke S., Franck T., Gangl M., Péters F., Salciccia A., Deby-Dupont G., et al., Myeloperoxidase assay in plasma and peritoneal fluid of horses with gastrointestinal disease, Can. J. Vet. Res., 2008, 72, 37-2
  52. Kruidenier L., Kuiper I., Lamers C.B., Verspaget H.W., Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants, J. Pathol., 2003, 201, 28-6 CrossRef
  53. Cruz T., Gμlvez J., Crespo E., Ocete M.A., Zarzuelo A., Effects of silymarin on the acute stage of the trinitrobenzenesulphonic acid model of rat colitis, Planta Med., 2001, 67, 94-6 CrossRef
  
• 作者单位：Hadi Esmaily (1)
  Azadeh Hosseini-Tabatabaei (1)
  Reza Rahimian (1)
  Reza Khorasani (1)
  Maryam Baeeri (1)
  Ahmadreza Barazesh-Morgani (1)
  Nargues Yasa (2)
  Yassaman Khademi (1)
  Mohammad Abdollahi (1)
  
  1. Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences (TUMS), 1417614411, Tehran, Iran
  2. Medicinal Plants Research Center, TUMS, 1417614411, Tehran, Iran
  
• ISSN：1644-3632

文摘

Inflammatory bowel disease (IBD) is a multifactorial disease with an unknown etiology characterized by oxidative stress, leucocyte infiltration and a rise in inflammatory cytokines. In this study, we have investigated the effects of silymarin, a mixture of several flavonolignans with established antioxidant and anti-inflammatory properties, on trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. Experimental colitis was induced in male Wistar-albino rats by delivering TNBS to the distal colon. All the medicines were administered by gavage for seven days. Thirty-six male rats were divided into six groups containing six rats in each one. Control rats received only TNBS. In the treated groups, animals were given different doses of silymarin (40, 80, and 160 mg/kg). Dexamethasone (1 mg/kg) was used as the positive treatment. Colonic status was investigated seven days post induction of colitis through macroscopic, histological, and biochemical analyses. Amelioration of the morphological signs including macroscopic damage, necrotic area, and histology were seen subsequent to treating animals with silymarin. These observations were accompanied by a significant reduction in the degree of both neutrophil infiltration, indicated by decreased myeloperoxidase activity, and lipid peroxidation, as measured by a decline in malodialdehyde content in inflamed colon as well as a decrease in levels of inflammatory cytokines (TNF-α and IL-1β). The results of the present study reveal that the beneficial effect of silymarin in bowel cells is mediated through its anti-oxidant and anti-inflammatory potentials.